Case Study: AstraZeneca Protocol D8460C00004
A weight loss study evaluating subcutaneous treatment with AZD9550 and AZD6234 in combination against placebo or each of the drugs alone
Study Objectives and Results
Objectives
- Global Enrollment Goal: 360 Participants
- QCR Enrollment Goal: 5 Participants
- Enrollment Window: 2 Months
- Target Population: Adults aged 19-75
- Disease Characteristics: Have a BMI ≥ 30 or ≥27 with Hypertension or Dyslipidaemia
Quality Clinical Research achieved its enrollment goal 15 days before the enrollment window closed. Given this success, QCR was authorized to enroll beyond its initial target. This study had competitive enrollment and QCR outpaced average site enrollment. QCR’s contribution underscored its ability to exceed ambitious enrollment goals, reflecting its operational excellence.
The average study screen fail rate for other research sites was 70%. QCR achieved a screen fail rate of 12.5% due to diligent medical record review and prescreening procedures.
Result 01
8 Patients Enrolled
Result 02
2.2% of Trial Population
Result 03
Outpaced Average Site Enrollment
